The present application is directed to compounds of the following formula andpharmaceuticallyacceptable salts, esters, and prodrugs thereof which are inhibitors of Sykkinase. Also disclosedare intermediates used in making such compounds, the preparation of such acompound,pharmaceutical compositions containing such a compound, methods of inhibitionSyk kinaseactivity, methods of inhibition the platelet aggregation, and methods toprevent or treat a numberof conditions mediated at least in part by Syk kinase activity, such as NonHodgkin's Lymphoma.(see above formula)
